F
Fundacion Respirar | Clinical Independency Research
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
Nivolumab
Bemarituzumab
LY3009104
Baricitinib
Povorcitinib
Parent organization
This site is a part of Fundacion Respirar
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
3 of 3 total trials
Locations recently updated
The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).
Active, not recruiting
Alopecia Areata
Drug: Baricitinib
Drug: Placebo
The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function
Enrolling
Moderate to Severe Asthma
Drug: ICS-LABA
Other: placebo
Locations recently updated
The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6)...
Enrolling
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Other: Placebo
Drug: Nivolumab
Trial sponsors
Clinical trials
Research sites
Resources
Legal
© Copyright 2024 Veeva Systems